Abstract：Objective: To explore the clinical efficacy and adverse reactions of probiotic combination with pyrotinib and capecitabine for the treatment of HER-2 positive advanced breast cancer, with a view to providing a reference for clinical treatment plans.Methods: One hundred and five HER-2 positive breast cancer patients were selected from January 2019 to August 2023 in the Affiliated Tumor Hospital of Guangxi Medical University and were divided into the study group and the control group by randomized numerical table method, and the numbers of cases were 53 and 52, respectively. The study group was treated with probiotics + pyrotinib + capecitabine, and the control group was treated with pyrotinib + capecitabine. The two groups were compared in terms of recent efficacy, the number of major intestinal flora colonies before and after chemotherapy, T-lymphocyte subsets (CD3+, CD4+, CD4+/CD8+), inflammatory factors [interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor cell necrosis factor-alpha (TNF-alpha)], and the degree of cancer-caused fatigue [Piper Fatigue Scale (PFS) score], sleep quality [Pittsburgh Sleep Quality Index (PSQI) score], quality of life [European Organization for Research and Treatment of Cancer Quality of Life questionmaire core 30 (EORTC QLQ-C30) score], and adverse effects.Results: The total remission rate of the two groups was not statistically significant (P>0.05), but the rate of discontinuing or lowering the dose of pyrotinib due to adverse reactions was lower in the study group than in the control group (P<0.05); the number of bifidobacteria and Lactobacillus colonization was higher than that of the control group, and the number of Escherichia coli and enterococci colonization was lower than that of the control group after 2 cycles of treatment in the study group, and 4 cycles later (P<0.05); the number of peripheral blood CDs was higher than that of the control group after 2 cycles of treatment in the study group. After 2 cycles of treatment, peripheral blood CD3+, CD4+, CD4+/CD8+ levels were higher than those of the control group (P<0.05); serum IL-6, IL-8, TNF-α levels were lower than those of the control group after 2 cycles of treatment and after 4 cycles of treatment in the study group (P<0.05); PFS and PSQI scores were lower than those of the control group after 2 cycles of chemotherapy and after 4 cycles of chemotherapy in the study group, and EORTC QLQ- C30 score was higher than that of the control group (P<0.05); the incidence of diarrhea in the study group was lower than that of the control group (P<0.05), and the difference in the incidence of hand-foot syndrome, leukopenia, neutropenia, and thrombocytopenia was not statistically significant when compared with that of the control group (P>0.05).Conclusion: Probiotic can promote the improvement of immune function in HER-2 positive breast cancer patients after treatment with pyrotinib combined with capecitabine, which can effectively reduce the occurrence of gastrointestinal-related adverse reactions, thus improving the quality of patient survival.
周文献, 谭爱花, 王洪学, 贾昱娴, 覃芳卉. 益生菌在卡培他滨联合吡咯替尼治疗晚期乳腺癌中的作用探讨[J]. 河北医学, 2024, 30(11): 1918-1924.
ZHOU Wenxian, TAN Aihua, WANG Hongxue, et al. The Effect of Probiotics on the Efficacy and Adverse Reactions of Breast Cancer Chemotherapy Combined with Targeted Therapy. HeBei Med, 2024, 30(11): 1918-1924.
[1] Burstein HJ,Curigliano G,Thürlimann B,et al.Gallen international consensus guidelines for treatment of early breast cancer 2021[J].Ann Oncol,2021,32(10):1216-1235. [2] 王仙玲,蒋倩.放疗联合吡咯替尼治疗人表皮生长因子受体2阳性乳腺癌脑转移患者的效果及安全性[J].肿瘤研究与临床,2024,36(8):622-625. [3] 董拓周,公雪,李大林.菌群移植联合PD-L1抑制剂及化疗治疗三阴性乳腺癌的展望[J].现代肿瘤医学,2023,31(6):1177-1180. [4] Mouabbi JA,Hassan A,Lim B,et al.Invasive lobular carcinoma:an understudied emergent subtype of breast cancer[J].Breast Cancer Res Treat,2022,193(2):253-264. [5] Kolarova I,Melichar B,Vanasek J,et al.Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2021,165(1):19-25. [6] Ma F,Ouyang Q,Li W,et al.Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes,anthracyclines,and/or trastuzumab:a randomized,phase Ⅱ study[J].Clin Oncol,2019,37(29):2610-2619. [7] Thu MS,Ondee T,Nopsopon T,et al.Effect of probiotics in breast cancer:a systematic review and meta-analysis[J].Biology (Basel),2023,12(2):280. [8] Shimizu K,Ojima M,Ogura H.Gut microbiota and probiotics/synbiotics for modulation of immunity in critically Ill patients[J].Nutrients,2021,13(7):2439. [9] 梁志,王继军,李鹏达,等.口服益生菌对结直肠癌化疗患者免疫力影响的Meta分析[J].现代消化及介入诊疗,2021,26(10):1271-1275. [10] 唐君媛,张桂新,陈琳,等.塞来昔布联合化疗对晚期非小细胞肺癌合并慢性阻塞性肺疾病患者的抗炎作用及其机制研究[J].中国现代医学杂志,2023,33(17):23-29. [11] Chandel D,Sharma M,Chawla V,et al.Isolation,characterization and identification of antigenotoxic and anticancerous indigenous probiotics and their prophylactic potential in experimental colon carcinogenesis[J].Sci Rep,2019,9(1):14769. [12] 郭楠楠,武宜婷,赵峰,等.双歧杆菌在胃癌FOLFOX6方案化疗中的作用研究[J].蚌埠医学院学报,2021,46(11):1510-1512,1516.
2024, Vol. 30 
冀公网安备13080202000677号